Buscar
Mostrando ítems 11-20 de 202
Revisión del uso de los medicamentos biosimilares vs. biológicos: implicaciones para la salud en Colombia.
(Universidad del RosarioMaestría en Administración en SaludFacultad de administración, 2016)
This paper aims to describe the health implications with the use of biosimilars compared with biological drugs in Colombia. Also, described the regulatory context about the use of biosimilars, recommendations and guidelines ...
Practical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin America
(Springer, 2019)
The use of biosimilar drugs for multiple sclerosis (MS) has become widespread in Latin America, with the goal of reducing costs of treatments, promoting the sustainability of healthcare systems, and improving patient ...
Medicamentos biológicos y biosimilares: más allá del horizonte terapéutico
(Asociación Colombiana de Dermatología y Cirugía DermatológicaCentro de de Investigaciones DermatológicasBogotá, Colombia, 2022)
A bibliometric analysis of the global research on biosimilars
(BioMed Central, 2018)
Background: Biosimilars could be a promising option to help decrease healthcare costs and expand access to treatment. There is no previous evidence of a global bibliometric analysis on biosimilars. Therefore, we aimed to ...
Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America
(Wiley Blackwell, 2016)
Latin American countries view biosimilar agents as an effective approach to curtail health-care expenditures while
maintaining the safety and efficacy profile of their branded innovator comparators. To understand the ...
Comparative analysis of the biosimilar and innovative G-CSF modulated pathways on umbilical cord blood–derived mononuclear cells
(SAGE Publications, 2020-03-20)
Biosimilars of granulocyte colony-stimulating factor (G-CSF) have been routinely introduced into clinical practice. However, not functional genomics characterization has been performed yet in comparison with the innovator ...
Multiplexed Gene Expression as a Characterization of Bioactivity for Interferon Beta (IFN-β) Biosimilar Candidates: Impact of Innate Immune Response Modulating Impurities (IIRMIs)
(Springer, 2019)
Recombinant human interferon-β (rhIFN-β) therapy is the first-line treatment in relapsing-remitting forms of multiple sclerosis (MS). The mechanism of action underlying its therapeutic activity is only partially understood ...
Erythropoietin treatment in chronic renal failure anaemia-biosimilar option in the rational use of medicine process in order to reduced public health economic burden
(OMICS Publishing Group, 2018-08)
Biopharmaceuticals innovation molecules have changed the course of a large number of chronic diseases. Many of these molecules became Gold Standards in oncology, rheumatology and other illness. However, their cost makes ...
Development Of Biosimilars In Brazil [desenvolvimento De Biossimilares No Brasil]
(OpenJournals Publishing, 2016)